Interview with Mark Rothera, PTC Therapeutics

Email address:

First name:

Last name:

Job title:

Company name:

Country:

I work for

Please specify your industry *

Mobile number:

What is your role?

Remember my details Information

Remember my details

We place a 'cookie' on your computer so next time you visit us you don't need to fill in all these details

close »

Interview with Mark Rothera, PTC Therapeutics

Download this eBook now to find out more about:

Game-changer Translarna for over 2,000 rare diseases with a nonsense mutation. What makes Translarna unique?
What’s next for Translarna after the latest Phase 3 clinical trials
Reactions to Biomarin’s previously GSK/Prosensa’s orphan drug disappointing Ph 3 study results and the pending Sarepta results
How to choose which to prioritize from among the 2,000 rare diseases with a nonsense mutation
The most challenging part in getting approval in Europe
How early collaboration with regulators should be
What processes or steps helped along this regulatory collaboration and approval
Market access
At what point would PTC sell

And of course a sneak preview of Mark's keynote session at the World Orphan Drug Congress USA next April.

Get your copy here >